Chapter 7: Idiopathic Membranous Nephropathy

Overview

Journal Kidney Int Suppl (2011)

Publisher Elsevier

Specialty Nephrology

Date 2014 Jul 15

PMID 25018932

Citations 32

Affiliations

Soon will be listed here.

Citing Articles

Effects of immunosuppressive therapy on renal prognosis in primary membranous nephropathy.

Li W, Cen J, Qi D, Guan M, Chen J, Qin X BMC Nephrol. 2024; 25(1):377.

PMID: 39449118 PMC: 11515281. DOI: 10.1186/s12882-024-03796-4.

Efficacy and safety of Mahuang Fuzi and Shenzhuo Decoction for treatment of primary membranous nephropathy: a multicenter prospective trial.

Zhang N, Jiang H, Dai H, Huang S, Zhao Q, Zhang N Ren Fail. 2024; 46(1):2320834.

PMID: 38482580 PMC: 10946256. DOI: 10.1080/0886022X.2024.2320834.

Clinicopathological characteristics and outcomes of PLA2R related idiopathic membranous nephropathy in patients with seronegative PLA2R antibodies.

Li X, Shen Y, Li Y, Ma L, Sun Q Ren Fail. 2024; 46(1):2297015.

PMID: 38275176 PMC: 10823883. DOI: 10.1080/0886022X.2023.2297015.

Membranous nephropathy.

Dantas M, Silva L, Maciel Pontes B, Dos Reis M, de Lima P, Neto M J Bras Nefrol. 2023; 45(2):229-243.

PMID: 37527529 PMC: 10627124. DOI: 10.1590/2175-8239-JBN-2023-0046en.

The efficacy and safety of Sanqi Qushi Granule in patients with idiopathic membranous nephropathy --protocol of a multicenter, randomized control trial (SQ-AUTUMN).

Li C, Shan W, Liang X, Zhang Q, Qin X, Jiang S BMC Complement Med Ther. 2023; 23(1):134.

PMID: 37106336 PMC: 10134584. DOI: 10.1186/s12906-023-03950-9.

References

. Controlled trial of azathioprine in the nephrotic syndrome secondary to idiopathic membranous glomerulonephritis. Can Med Assoc J. 1976; 115(12):1209-10. PMC: 1878979. View

Tsukahara H, Takahashi Y, Yoshimoto M, Hayashi S, Fujisawa S, Suehiro F . Clinical course and outcome of idiopathic membranous nephropathy in Japanese children. Pediatr Nephrol. 1993; 7(4):387-91. DOI: 10.1007/BF00857546. View

Trainin E, Boichis H, Spitzer A, GREIFER I . Idiopathic membranous nephropathy. Clinical course in children. N Y State J Med. 1976; 76(3):357-60. View

Chen M, Li H, Li X, Lu F, Ni Z, Xu F . Tacrolimus combined with corticosteroids in treatment of nephrotic idiopathic membranous nephropathy: a multicenter randomized controlled trial. Am J Med Sci. 2010; 339(3):233-8. DOI: 10.1097/MAJ.0b013e3181ca3a7d. View

Praga M, Barrio V, Juarez G, Luno J . Tacrolimus monotherapy in membranous nephropathy: a randomized controlled trial. Kidney Int. 2007; 71(9):924-30. DOI: 10.1038/sj.ki.5002215. View

. Nephrotic syndrome in children: prediction of histopathology from clinical and laboratory characteristics at time of diagnosis. A report of the International Study of Kidney Disease in Children. Kidney Int. 1978; 13(2):159-65. DOI: 10.1038/ki.1978.23. View

Glassock R . Diagnosis and natural course of membranous nephropathy. Semin Nephrol. 2003; 23(4):324-32. DOI: 10.1016/s0270-9295(03)00049-4. View

du Buf-Vereijken P, Branten A, Wetzels J . Cytotoxic therapy for membranous nephropathy and renal insufficiency: improved renal survival but high relapse rate. Nephrol Dial Transplant. 2004; 19(5):1142-8. DOI: 10.1093/ndt/gfh036. View

Nasr S, Said S, Valeri A, Stokes M, Masani N, DAgati V . Membranous glomerulonephritis with ANCA-associated necrotizing and crescentic glomerulonephritis. Clin J Am Soc Nephrol. 2009; 4(2):299-308. PMC: 2637583. DOI: 10.2215/CJN.04060808. View

10.

Erwin D, Donadio Jr J, HOLLEY K . The clinical course of idiopathic membranous nephropathy. Mayo Clin Proc. 1973; 48(10):697-712. View

11.

Beck Jr L, Bonegio R, Lambeau G, Beck D, Powell D, Cummins T . M-type phospholipase A2 receptor as target antigen in idiopathic membranous nephropathy. N Engl J Med. 2009; 361(1):11-21. PMC: 2762083. DOI: 10.1056/NEJMoa0810457. View

12.

Pei Y, Cattran D, Greenwood C . Predicting chronic renal insufficiency in idiopathic membranous glomerulonephritis. Kidney Int. 1992; 42(4):960-6. DOI: 10.1038/ki.1992.374. View

13.

Ramirez F, Brouhard B, Travis L, Ellis E . Idiopathic membranous nephropathy in children. J Pediatr. 1982; 101(5):677-81. DOI: 10.1016/s0022-3476(82)80289-8. View

14.

Shearman J, Yin Z, AARONS I, Smith P, Woodroffe A, Clarkson A . The effect of treatment with prednisolone or cyclophosphamide-warfarin-dipyridamole combination on the outcome of patients with membranous nephropathy. Clin Nephrol. 1988; 30(6):320-9. View

15.

Cattran D, Greenwood C, Ritchie S, Bernstein K, Churchill D, Clark W . A controlled trial of cyclosporine in patients with progressive membranous nephropathy. Canadian Glomerulonephritis Study Group. Kidney Int. 1995; 47(4):1130-5. DOI: 10.1038/ki.1995.161. View

16.

Row P, Cameron J, Turner D, Evans D, White R, Ogg C . Membranous nephropathy. Long-term follow-up and association with neoplasia. Q J Med. 1975; 44(174):207-39. View

17.

Kuroki A, Shibata T, Honda H, Totsuka D, Kobayashi K, Sugisaki T . Glomerular and serum IgG subclasses in diffuse proliferative lupus nephritis, membranous lupus nephritis, and idiopathic membranous nephropathy. Intern Med. 2002; 41(11):936-42. DOI: 10.2169/internalmedicine.41.936. View

18.

Fervenza F, Abraham R, Erickson S, Valentina Irazabal M, Eirin A, Specks U . Rituximab therapy in idiopathic membranous nephropathy: a 2-year study. Clin J Am Soc Nephrol. 2010; 5(12):2188-98. PMC: 2994079. DOI: 10.2215/CJN.05080610. View

19.

Laluck Jr B, Cattran D . Prognosis after a complete remission in adult patients with idiopathic membranous nephropathy. Am J Kidney Dis. 1999; 33(6):1026-32. DOI: 10.1016/S0272-6386(99)70138-1. View

20.

Falk R, Hogan S, Muller K, Jennette J . Treatment of progressive membranous glomerulopathy. A randomized trial comparing cyclophosphamide and corticosteroids with corticosteroids alone. The Glomerular Disease Collaborative Network. Ann Intern Med. 1992; 116(6):438-45. DOI: 10.7326/0003-4819-116-6-438. View